Environmental Clean Technologies (ASX:ECT) puts COLDry on the table after 20 years of waiting

RSM has been brought in to decide if the lignite technology is finally a business

Twenty years is a long time to develop a single piece of technology without a clear commercial outcome. So when Environmental Clean Technologies (ASX:ECT) told the market today that it has formally engaged RSM Corporate Australia to run an independent commercialisation review of its COLDry lignite processing technology, the message landed with a particular kind of weight.

COLDry is ECT’s proprietary low-temperature method for turning lignite, which is the soft brown coal mined in places like the Latrobe Valley, into a stable, value-added product. The most active current application sits in agriculture, where the processed material is being shaped into fertiliser and soil health products through ECT’s relationship with Zero Quest Pty Ltd.

The review will look at two things. What ECT does with its existing Zero Quest arrangement, and what other applications, partners or licensing structures might extract more value from the technology. Executive Chairman Faldi Ismail framed it as the Board considering the full range of opportunities, which is corporate language for everything is now on the table.

For shareholders who have watched COLDry inch toward commercialisation for over two decades, this is either the moment the story finally clicks or the moment the Board admits the current pathway is not the right one.

Why bring in RSM now, and what that signals

Engaging an external corporate advisory firm to run a structured commercial and financial review is not a small step. It typically signals one of two things. Either inbound interest has reached a level where the Board needs independent advice to negotiate properly, or internal confidence in the current pathway has eroded enough that fresh eyes are required.

The announcement points more toward the first read. ECT specifically notes that COLDry’s ability to turn lignite into a downstream-ready product has generated increasing commercial interest, which is the kind of language companies use when they have had conversations they cannot yet name. Our take is that the Zero Quest relationship is almost certainly part of what is being reassessed, not just expanded.

RSM will assess commercial merits, risks, capital requirements and timeframes across the various pathways. That is a broad brief, and it tells you the Board is genuinely undecided about the optimal structure rather than seeking validation of a plan already chosen.

The Zero Quest question sitting underneath all of this

The most interesting line in the announcement is that ECT will consider its strategic relationship with Zero Quest and the range of options available regarding future participation in agricultural applications. ECT owns the exclusive licence to COLDry, but the fertiliser product development and commercialisation activities sit with Zero Quest independently.

That structural split matters. If the fertiliser product gains real commercial traction, ECT participates through its licensing arrangement rather than through direct ownership of the end product. The review is likely examining whether that economic split still makes sense, or whether ECT should be pushing for a different structure, a different partner, or a parallel pathway in another vertical entirely.

Worth noting that ECT also flagged a delay in the A$1.3 million Yallourn property sale announced in March, with due diligence extended by up to two months. It is not material to the COLDry story, but it does reinforce the picture of a company actively cleaning up its asset base while the strategic review runs.

What this means for a stock that has tested patience

ECT is a sub-cent penny stock with a long history of milestones that did not convert into revenue. The skeptical read is that a commercialisation review is the kind of process announcement that buys management another six to twelve months without committing to anything concrete.

The more constructive read is that bringing in RSM creates an external deadline and a structured output. Boards do not engage corporate advisory firms to produce reports that get filed and ignored. There will be a recommendation, and the market will get to judge whether ECT acts on it.

The Investors Takeaway for Environmental Clean Technologies

We think the next genuine catalyst for ECT is not another technical milestone or another agricultural trial result. It is the conclusion of this review and the Board decision that follows. A licensing deal with a named counterparty, a restructured Zero Quest arrangement, or a clear pivot to a different application would all be material.

What would not be material is a review that ends with a vague commitment to continue exploring options. Investors should set a mental clock on this. Reviews of this kind typically run three to six months, which puts a meaningful update on the table before year end. Readers interested in similar small-cap technology commercialisation stories can find broader ASX coverage at stocksdownunder.